Gossamer Bio raises $25M initial private placement, up to $225M more tied to FDA milestones

Gossamer Bio, Inc.

Initial closing expected Aug 24, 2026: ~$25M gross from pre-funded warrants at $0.1399/share.
Second closing of ~$125M upon FDA acceptance of NDA for seralutinib in PAH; FDA Approval Warrants add ~$100M.
Proceeds to fund clinical development and commercialization of seralutinib in PAH and PH-ILD.
Warrants exercisable for preferred stock pre-stockholder approval, then common stock; conversion prices $0.14 and $0.187.
Company lock-up until FDA approval warrants exercised or Dec 31, 2026 if second closing not met.

item 1.01 item 3.02 item 5.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.